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1. Introduction 
1.1 Definition of nuclear medicine, molecular imaging and hybrid imaging 
Nuclear Medicine uses radioactive probes commonly referred to as tracers for the 
diagnosis and treatment of diseases. Monitoring the metabolic fate of nanomolar amounts 
of radiolabeled substances by tracking their photon emission with SPECT (Single Photon 
Emission Tomography) and PET (Positron Emission Tomography) was the first widely 
practiced branch of Molecular Imaging (MI). MI is the visualization, characterization and 
measurement of biological processes at the molecular and cellular levels in humans and 
other living systems (Mankoff, 2007). Among the different techniques summarized in MI, 
tracer imaging in Nuclear Medicine has the highest molecular sensitivity, tracing 
substances in the 10E-3 to 10E-5 mol/l range. Conventional imaging with x-ray was 
primarily used as a snapshot of anatomy and depicts tissue by its physical characteristics 
(e.g., X-ray density). Contrast agents in CT are used to increase the visibility of vessels 
and organ surfaces. Functional information is at best limited to that of perfusion and 
permeability. This is one of the most significant differences between Radiology and 
Nuclear Medicine.  
The advantage of functional imaging is that of increasing sensitivity because metabolic 
changes precede anatomical changes and can be detected long before structural changes 
appear. Functional imaging, however, has a low specificity in distinctly different 
pathologies (e.g., degenerative, inflammatory or malignant bone lesions) if they are 
visualized by unspecific common properties as hyperaemia, increased regional tracer 
permeability and osteoplastic metabolism. To overcome this and to increase specificity, 
highly specific probes (e.g., receptor imaging) have been developed. With minimal uptake 
outside the targeted tissues, specific probes offer little information about the surrounding 
tissues and consequently do not provide the topographical information needed by surgeons 
or therapy planning systems in radio oncology. The advantage of anatomical imaging by CT 
is its high anatomical resolution and usually good topographical information. On the other 
hand it is a poor predictor of the functional consequences of a finding (e.g., borderline 
stenosis in coronary CT angiography) and consequently a poor predictor of prognosis. 
Structural data do not necessarily correlate with the metabolic status of disease and they 
have a limited diagnostic sensitivity in cases with abnormal anatomy (e.g., scar versus 
residual tumour). Anatomic tumour response metrics (WHO criteria, Response Evaluation 
Criteria in Solid Tumours (RECIST)) are insufficient to predict therapy response, 
particularly in assessing the activity of newer cancer therapies that stabilize disease and may 
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be substituted by quantitative approaches in functional imaging (PET Response Criteria in 
Solid Tumours; PERCIST (Wahl et al 2009)). An ideal non-invasive technique provides 
complementary information on topography and anatomy as well as on the functional 
behaviour of a lesion.  
Less than one decade ago, primarily forced by the manufacturers, hybrid devices were 
brought into clinical routine. It took only a few years after the first description of a working 
prototype (Beyer et al., 2000) to replace stand-alone PET by PET/CT. A similar success story 
may be appreciated with SPECT/CT (Schillaci et al., 2005). However, the development of 
hybrid imaging in PET and SPECT followed different pathways. Whereas PET was always 
combined with a state-of-the-art CT system, the first SPECT/CT design was based on a low-
current, slow revolving CT (see chapter 2). Both hybrid devices have been shown to 
improve diagnosis and risk stratification by combining anatomical and functional 
information (see chapters 4 and 5).  
Nuclear Medicine interpretation benefits from CT in three ways:  
Firstly, scintigraphic uptake can now be localized topographically and enables local 
interventions (e.g., surgery, radio therapy planning). Secondly, physiological and 
unphysiological tracer uptake can be better discriminated by visualizing the anatomical 
background (e.g. FDG uptake in brown adipose tissue). Thirdly, an often overlooked 
advantage is that the CT attenuation map shortens imaging protocols and possibly improves 
attenuation and scatter correction of PET and SPECT.  
On the other hand, Nuclear Medicine may also improve CT interpretation, e.g. in the 
differential diagnosis of minimally enlarged mediastinal or retroperitoneal lymph nodes 
and in therapy monitoring.  
1.2 Is hybrid imaging the final answer to all our needs? 
The complementary information of anatomical and functional imaging has been used for 
decades to define, characterize, stage and monitor disease, but until recently the different 
modalities have been performed in sequence (e.g. screening for bone metastases by whole 
body bone scanning followed by planar radiographs and possibly MRI). Before hybrid 
systems (PET/CT, SPECT/CT) came into the market the findings of different modalities had 
to be independently viewed or (as discussed in chapter 3.) digitally fused. The coming of 
hybrid devices was welcomed by many with overwhelming optimism (von Schulthess et al., 
2002), but a more thorough assessment of the matter surfaces several unsolved problems 
which will be addressed below. Sceptics may even say that we – driven by the market and 
our own curiosity - have opened Pandora’s box.  
1.3 What is the incremental benefit of simultaneous hybrid imaging to the sequential 
use of optimized imaging? 
The most obvious answer to this question seems to be that patient positioning and 
movement is not an issue in simultaneous hybrid imaging but sime of these problems may 
have not been eliminated. Modern systems combine both modalities on a single gantry, but 
different detectors are still needed to image both signals and both studies are acquired 
sequentially. The problems of misalignment of both investigations are discussed in detail in 
1.6.1. The strongest evidence for the clinical effectiveness of FDG-PET is in staging NSCLC, 
restaging HL, staging/restaging colorectal cancer and detection of solitary pulmonary 
nodule (Facey et al., 2007). Numerous studies with a heterogeneous design claimed that the 
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incremental benefit of simultaneous hybrid imaging to sequential protocols is well over 10 
% at least in oncology (Czernin et al., 2010, Delbecke et al., 2009).  
1.4 Can the additional accuracy be utilized in clinical practice? 
The cost-effectiveness of a PET plus CT strategy was shown as early as in the late 90s 
(Gambhir et al., 1996) for diagnosis and staging of lung cancer and numerous other 
indications followed. Nevertheless especially in follow-up investigations, it all comes down 
to this:  
Does the additional information affect clinical decisions in a significant number of patients 
and do they benefit from the additional information provided by advanced imaging?  
There is some evidence in oncology that hybrid imaging has changed patient management 
(Almuhaideb  et al. 2001, Facey et al., 2007). In cardiology the addition of calcium scoring 
has been described to improve the results of myocardial perfusion SPECT (Mahmarian, 
2007). Though sometimes quoted (Farid et al., 2009) data are scarce that hybrid imaging in 
neurology has an additional advantage to digital image fusion.  
1.5 Is the additional radiation burden of multiple diagnostic CTs worthwhile? 
In Nuclear Medicine imaging can be performed as whole body imaging or dual phase 
protocols without additional radiation exposure. In contrast, multi-phase CT protocols and 
larger scanning volumes inevitably increase the radiation burden of the patient. Routinely 
combining PET or SPECT with diagnostic whole body CT unnecessarily increases the 
radiation dose in some patients. “Low dose CT” (for a definition see 2.2.) appears to be a good 
compromise, but it may overlook minute pathologies that show no tracer uptake but could 
have been revealed by a diagnostic CT. Diagnostic CTs in radiology (in contrast to low-dose 
CTs in Nuclear Medicine) are routinely acquired during maximum inspiration, increasing the 
intrathoracic volume, moving the diaphragm downwards and changing the relative organ 
positions in comparison to the situation during the PET/SPECT acquisition. A mid expiratory 
position would be a good compromise but is difficult to reproduce voluntarily (Pan et al., 
2005) and it has yet to be determined to what extent this hampers the diagnostic accuracy of 
the CT in the lung. A step wise approach should be ideal but this is very difficult to implement 
into the busy scheduling of diagnostic imaging when all too often the tentative diagnosis of the 
referrer is imprecise and it is hard to decide the necessary depth of the diagnostic protocol. 
Thus, at present many CTs will be duplicated in hybrid imaging. 
1.6 Is the CT information fully utilized in the reconstruction of PET and SPECT 
imaging? 
Until recently most reviews about hybrid imaging have focused on the clinical advantages 
due to the better anatomical allocation of PET/SPECT images, but at least in PET/CT the 
biggest advantage was that of improving image reconstruction by speeding the transmission 
scan. Coincidence imaging in PET and Single Photon imaging in SPECT imaging, though 
completely different in some of their physical basics, need several corrections to improve 
imaging and to allow quantification, with attenuation and scatter correction being the most 
important. Whereas these corrections are now regarded as mandatory in PET, they may gain 
importance in quantitative SPECT, but at present are only implemented in myocardial 
perfusion imaging and brain imaging. Initially both, PET and SPECT, used radioactive 
sources for transmission imaging, but attenuation maps generated from CT scans can be 
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acquired much faster. However, three issues may hamper this approach: Misalignment, 
energy dependent attenuation and CT artefacts. 
1.6.1 Misalignment 
Misalignment of both studies cannot be avoided completely as different detectors are 
needed to image signals from radionuclides and x-ray tubes (Goetze & Wahl, 2007). Both 
studies are acquired sequentially and differ significantly in imaging duration thus causing 
head, whole-body and extremity motion, diaphragmatic motion with breathing and bowel 
motility (Figure 1). The different expiratory positions between CT and PET/SPECT have 
been addressed in 1.5.  
 
 
Fig. 1. FDG PET/CT with minimal head movement between both investigations 
1.6.2 Energy dependent attenuation 
The different energy spectrums of Nuclear Medicine tracers (PET monoenergetic 511-keV 
photons, SPECT mono- and multienergetic photons in a wide range of energies) and CT 
pose another challenge.  The spectrum of photons energy from the anode of the x-ray tubes 
used in CT range from 0 keV up to peak energy used for the acquisition. Attenuation 
increases with lower energy this may cause artefacts, like beam-hardening effects. So, 
filtering of the beam is required. The resulting spectrum has a mean energy of about 70 keV. 
At the low energy level of some SPECT tracers (e.g., 68-80 keV (94.5%) Tl-201) and CT 
photons, interaction with body tissues takes place in part through photoelectric effects, 
whereas the high energy 511-keV annihilation photons used for PET are almost exclusively 
attenuated by Compton scattering. The attenuation coefficients need to be scaled 
appropriately in each energy window for the different materials (air, soft tissue, bone). This 
is more complex for SPECT than for PET, due to the wide range and sometimes multiplicity 
of energy windows of the used radioisotope. Before CT data can be used for attenuation 
correction in PET and SPECT, CT voxel sizes have to be downscaled due to the lower spatial 
resolution of those devices (Krishnasetty et al., 2008) and segmented according to the 
different materials. The used algorithms differ between different vendors and apparently 
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have been set for optimized visual diagnosis and not quantitative requirements. The 
consequences for quantitative PET/CT have been summarized elsewhere (Weber et al., 
2007). Until now quantitative SPECT was not a major issue but is rapidly emerging for 
diagnostic (fp-cit scan) imaging and dosimetry (Patton & Turkington, 2008).  
1.6.3 CT artefacts 
Attenuation artefacts (dental work, metallic implants) are other possible problems if CT is 
used for correction purposes in Nuclear Medicine imaging. Routine reconstruction for CT is 
filtered back projection and not iterative reconstruction and the first is especially susceptible 
to beam hardening artefacts if the patient does not fit into the field of view. This issue 
becomes more evident if low dose parameters are used and artefacts may hamper PET and 
SPECT reconstruction (Figure 2).  
 
 
Fig. 2. Beam hardening artefacts in a large patient (height: 175 cm, body weight: 120 kg) at 
the edge of the field of view are evident in the image of the low dose CT (140 kV, 230 mAs) 
on the left and have disappeared in the image on the right after conventional CT parameters 
(140 kV, 300 mAs) have been applied. 
This problem might be partially solved by using iterative reconstruction algorithm (Kinahan 
et al., 2003), but things get even more complicated if contrast media are involved in hybrid 
imaging (Büther et al., 2007). The different energy spectra of SPECT tracers pose an 
additional challenge to the reconstruction process if absolute quantification is aspired.  
1.7 Do we need hybrid imaging in all situations? 
Most likely not, but a more detailed analysis reveals a complex picture. Critics apparently 
have ample evidence of accusing our professions to succumb to a “the more the merrier” 
principle. We definitely have to provide evidence in which clinical situations hybrid 
imaging is warranted but then little is gained if a given diagnostic tool has shown to be the 
method of first choice in a certain situation, if this tool is not accessible: In most areas patient 
access to CT is much easier than to PET/CT or SPECT/CT thus many patients will already 
have a diagnostic CT before coming to Nuclear medicine imaging. This opens up the field 
for digital image fusion as described below (Chapter 3.).  
2. From low dose to multi-slice CT 
2.1 History and milestones 
The origins of PET, SPECT and CT date back into the early 1970s. Burnham et al. (1972) 
developed a multi-crystal positron camera. Modern PET scanners are based on the work of 
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Phelps et al (1975), Ter-Pogossian et al. (1975) and Hoffmann et al (1976). Almost in parallel 
in the early 1970s Ambrose & Hounsfield (1973) introduced a computerized x-ray tube-
based tomographic scanner providing images of tissue densities from acquired projections.  
In contrast to the evolution of SPECT/CT the first PET/CT scanner was developed as a 
combination of a then state-of-the-art spiral CT (Siemens Somatom AR) and a partial-slip-ring 
“poor man’s PET” (ECAT ART PET) on a common rotational support within a single gantry 
with the PET components on the reverse side of the rotating support of the CT scanner. This 
design reduced the expensive detectors from 144 to 66 and brought the price tag down to 
below 1 Million US $. Townsend et al., (1998) published their combination SMART scanner 
providing sequential imaging using the table as shuttle using the advantage of having the 
patient in the same body position without changing. Almost a decade later the first 
prototype SPECT/CT system was developed (Lang et al., 1991). This prototype used the 
same high-purity germanium detector array for both x-ray and single-photon imaging. The 
same group (Hasegawa et al., 1993) developed a different design by combining a CT scanner 
with a commercial gamma camera but it was not until the millennium when a different 
design became the first commercially available SPECT/CT system. This was in part 
triggered by the fact that this manufacturer (then ELSCINT, now General Electrics) was the 
first who used a slip ring for its gamma camera gantry, allowing > 360° rotation. This design 
was based on low speed. low current CT  (Hawkeye) that was explicitly developed for hybrid 
imaging with the Infinia gamma camera. At this time this was the logical approach as it 
provided sufficient topographic orientation and a transmission map for attenuation and 
scatter correction closely resembling the organ positions during the SPECT acquisition. The 
Hawkeye opened the market for SPECT-CT, but surprisingly or not in the end the market 
voted for other designs with MD CT scanners (Siemens, Philips). Siemens introduced the 
Symbia series in 2004 followed by Philips Precidence. Currently available SPECT/CT systems 
are: Discovery NM/CT 670 (General Electric), BrightView X/CT (Philips) and the Symbia T 
series (Siemens). Today PET/CT systems are only available with diagnostic CT scanners. 
The CT system can be operated at reduced tube current if only used for attenuation 
correction. The latest development in the history of PET/CT appears to be the marketing of 
a “CT/PET”. Siemens hides the fact that they are selling a PET/CT by naming it “molecular 
CT” (Biograph mCT). In 2008, the first hybrid PET/MRI system for humans was installed by 
Siemens (Pichler et al., 2008); but that is a completely different story.  
2.2 Radiation exposure in hybrid imaging 
Radionuclides used in PET and SPECT have a much lower photon flux and higher γ-rays 
energy in comparison to x-rays in CT. The effective dose caused by intravenously applied 
tracers in Nuclear Medicine is not only affected by the physical properties of the 
radionuclide but even more so by the biokinetics of the radiopharmaceuticals, thus in i.v. 
studies all organs are exposed to some extent. In contrast, the absorbed dose in CT is 
dependent on several operator dependent factors (mAs (directly proportional to radiation 
dose), kVp (not linearly proportional to dose), pitch (inversely related to dosage), slice 
thickness (smaller slices increase mAs), number of scans (multiplying radiation dose), scan 
time (faster scans lead to an increased scan area), scanning mode (step-based, spiral 
technique; single-slice, multi-slice) and proportional to the absorption coefficient of the 
irradiated tissue that is more or less limited to scanned body volume) (Bauhs et al., 2008). 
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Initially, attenuation correction for PET and SPECT was based on transmission scanning 
with radioactive sources (153-Gd for SPECT, 68-Ge for PET, respectively). Those sources 
exposed the patient to only low additional effective doses in the order of 0.1 to 0.2 mSv 
(Delbeke & Israel, 2010). Using CT as transmission source, especially in a diagnostic setting, 
the effective dose rises up to 100 times depending on the imaging protocols. A diagnostic CT 
of the chest, abdomen and pelvis will give an effective dose of about 13 mSv (140 kV, 340 
mAs, 0,5 s rotation time and a pitch fo 17.5 cm/s). On the other hand 18-F FDG PET (370 
MBq) causes an effective dose of about 11 mSv. The effective dose of SPECT varies, due to a 
wide range of different tracers. 99m-Tc (925 MBq) labelled white blood cell imaging is an 
investigation with one of the highest effective doses and delivers 18.5 mSv (Stabin et al., 
1996) to the patient. In commonly applied protocols in Austria (Stemberger et al., 2011) the 
contribution of the CT to the average total body effective dose is 14 mSv in PET/CT and 1-3 
mSv in SPECT/CT. Moving from diagnostic to “low dose” CT protocols lowers the effective 
dose considerably. Low dose CT is said to make up for only 10% to 15% of total effective 
dose in hybrid imaging, but some caution is advised: There is considerable confusion in the 
definition of the term “low dose” CT in hybrid imaging. Referring to the definition of the 
American College of Radiology (ACR) for Relative Radiation Level (RRL) values (Table 1), 
very few of the proposed protocols qualify for the definition of low radiation level. 
 
Radiation Level Effective Dose Range
None 0 
Minimal < 0.1 mSv 
Low 0.1 – 1 mSv 
Medium 1 – 10 mSv 
High > 10 mSv 
Table 1. Modified according to the ACR Appropriateness Criteria 
To put this into a clinical perspective, one has to address the issue how to quantify radiation 
risk: Basically, the effective dose does not reflect the individual risk but should be used to 
compare systems and to justify and optimize procedures. The individual risk is estimated by 
calculating mean doses of all organs and tissues in relation to age, sex and organ specific 
risk coefficients (ICRP 2007). The primary risk associated with radiation exposure in 
diagnostic imaging is the risk to develop cancer and this appears to be comparatively high. 
The seventh National Academy of Science report on Biological Effects of Ionizing Radiation 
estimated that a single dose of 10 mSv produces a lifetime risk of developing a solid cancer 
or leukemia of 1 in 1000 (BEIR VII 2006). This, however, has to be appreciated in the light of 
the chance of 1 in 4 dying from cancer in the developed countries. The most important way 
to reduce radiation dose in hybrid systems is to optimize the CT protocols. Most companies 
recommend protocols for optimal visual image quality but the question remains to what 
extent CT parameters can be modified to reduce dose without losing adequate information 
for attenuation correction, quantification and diagnostic information. Neuwirth et al., (2010) 
using a Siemens Biograph 64 PET/CT scanner showed that the attenuation correction of PET 
is not hampered even if the lowest possible CT parameters (80 keV, 28 mAs) are used. It 
goes without saying that those CT images contribute little diagnostic information. At 
present we lack sufficient data to quantify the diagnostic trade off between “low dose” and 
“diagnostic” CT. To this point we have only discussed the contribution of the x-ray tube and 
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radiopharmaceutical to the effective dose of the patient. Often neglected is the contribution 
of the scout scan or topogram used to determine scan limits before acquisition starts to total 
radiation exposition. A recent study (Moore et al., 2010) showed that the additional dose 
contributed by the topogram can be minimized (25 µGy) but in clinical routine it may be as 
high as 10 to 20% of the diagnostic CT scan depending on exposure time, region length, mA 
and voltage (O'Daniel et al., 2005). In principle, the topogram could be easily substituted in 
hybrid systems by the emission data of PET or SPECT but this option is still not available in 
all current hybrid designs as most are basically two devices glued together working 
independently.  
3. From digital Image fusion to hybrid imaging 
Before the advent of hybrid devices several steps had to be taken to allow digital image 
fusion of CT and Nuclear Medicine techniques.  Whereas Nuclear Medicine imaging became 
digital very early in its development, digital radiology emerged not before the late 80s. The 
second requirement was an interchangeable image format for both modalities. Initially 
images in Nuclear Medicine were stored in company proprietary formats. With several 
intermediate steps (e.g. interfile), the current definition of the DICOM standard 
(http://medical.nema.org/) allows handling, storing, printing, and transmitting of most 
study types in medical imaging. Nowadays accepted as natural law (Moore’s law), the 
gigantic boost in computer power was mandatory to implement sophisticated iterative 
reconstruction and fusion algorithms in clinical routine. Often overlooked, but sufficient in 
some clinical situations, even simple manual fusion has an incremental diagnostic impact 
over the separate analysis (Nakamoto et al., 2008). However, if image-guided interventions 
or sophisticated dosimetry is needed, digital fusion is a necessity. Numerous algorithms 
have been described to retrospectively align 3-dimensional data acquired by stand-alone 
modalities to common spatial coordinates (Slomka, 2004). Two basic approaches (internal 
landmarks or external fiducials) can and have been used to fuse tomographic images 
(Kramer et al., 1991; Kessler, 2006). Whereas external markers with individualized masks are 
routine procedures in radio oncology, they require considerable logistics, can only be used 
for small volumes and neglect information about internal organ displacements. Internal 
landmarks have the advantage of correcting for different organ positions and can be used 
even if the first study was acquired without the knowledge of a later image fusion but 
require substantial user interference which is prone to errors and may lack reproducibility. 
Basically all the used algorithms can be separated into feature or volume based approaches. 
The first align the two image sets according to extracted image features (e.g. anatomic 
landmarks, organ surfaces …) the latter maximize measures of similarity between images. 
Another important difference between these algorithms is if they are linear or nonlinear. 
Linear image fusion subjects all coordinates to the same extent of translation, rotation and 
scaling to be fused with the second study. This is perfect for the brain but insufficient for the 
non-rigid complex geometry of thoracic volumes. In contrast, nonlinear techniques are 
capable of fusing different intrathoracic volumes and to some extent different patient 
positioning but fail to correct for internal organ displacement, namely the liver. It has been 
reported that integrated PET/CT devices provided additional information in approximately 
6–7% of all lesions. However, in this report (Reinarzt et al., 2004) abnormal CT findings in 
the absence of increased 18F-FDG uptake were excluded, thus have not strictly investigated 
the additional benefit of the combined devices. Available evidence for the incremental 
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diagnostic utility of hybrid imaging in comparison to visual or digital fusion will be 
discussed below, but it is safe to predict that digital image fusion will continue to play an 
important role in patients with a previously performed diagnostic CT or MR.  
4. Current state of clinical PET/CT 
A recent survey showed PET is most frequently used in oncology (87%) followed by 
neurology (5%), radiation therapy planning and cardiology (4%), respectively. I.v. or oral 
contrast was used at 52% of the sites in up to 25% of patients but only 62% of the sites 
provided a fully integrated PET/CT report (Beyer et al., 2011). As stand alone PET systems 
have disappeared the clinical question is not if CT is used but to what extent (dose, contrast 
enhancement) it is performed as a diagnostic CT (Coleman et al., 2005). 
4.1 Oncology 
The utility of FDG PET in oncology has been recently summarized (Facey et al., 2007, 
Fletcher et al., 2008). PET/CT systems were not explicitly addressed due to the paucity of 
published data. Data for other PET tracers are not summarized here because of an even 
more limited database. Despite being the standard of care, there has been uncertainty about 
whether or not improved diagnostic accuracy translates into improved management of 
patients. The strongest evidence for the cost-effectiveness of PET is still in the staging of 
non-small cell lung cancer, but a recently performed analysis of FDG PET in oncology found 
only four studies (Mansueto et al., 2009, Lejeune et al., 2005, Krug et al., 2010, Yen et al., 
2009) that based their findings explicitly on PET/CT (Langer, 2010). The following overview 
tries to suggest clinical setting where growing evidence exists that the initial use of a 
diagnostic CT or if no access to hybrid imaging is possible, image fusion between CT and 
PET has to be aspired.  
4.1.1 Head neck cancer  
Accurate T and N staging requires contrast enhanced CT and PET and both investigations 
are complementary. Reactive lymph nodes in CT can be identified if FDG uptake is very low 
and necrotic lymph node metastases can be diagnosed in CT that are false negative in PET 
due to a low FDG uptake (Schöder et al., 2004, Jeong et al., 2004). However, as 40% of 
cervical metastases are below one centimeter in diameter not even PET/CT can confirm N0 
necks thus opening up the field for sentinel imaging (Hyde et al., 2003), possibly performed 
as SPECT/CT (see 5.1.3). Therapy monitoring should not be performed earlier than one 
month after therapy, due to a > 30% rate of false negatives (Rogers et al., 2004, Engles et al., 
2006). Restaging with FDG PET is more sensitive than CT/MR (Klabbers et al., 2003) but we 
lack data if PET/CT could further improve diagnosis. 
4.1.2 Lung cancer 
The sensitivity of integrated FDG PET/CT for mediastinal lymph node staging is low. 
PET/CT is superior to PET or CT alone, and visual correlation of both techniques separately. 
In particular, it improves T3 and T4 staging and delineation of tumours associated with 
atelectasis (Gámez et al., 2006). When positive mediastinal lymph nodes are detected, 
invasive mediastinal staging has been advised. On the other hand, the specificity is high: 
patients with negative integrated FDG PET-CT can be operated upon without invasive 
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mediastinal staging (Perigauda et al., 2009). Evidence accumulates that in patients with 
locally advanced NSCLC, quantitative analysis of a routine whole-body FDG PET/CT 
studies predicts tumour response to therapy (Eschmann et al., 2007). 
4.1.3 Esophageal cancer 
Endoscopic ultrasound (EUS) is superior to PET/CT for T staging and in identifying 
locoregional nodes but PET/CT has a high sensitivity and specificity for M staging. EUS and 
PET/CT independently affects treatment decisions, indicating complimentary and necessary 
roles in the staging (Walker et al., 2011). PET/CT is not sufficiently reliable in the individual 
patient for monitoring of treatment response but effective in detecting recurrent disease 
(Weber et al., 2001, Munden et al., 2006, Bruzzi et al., 2007, Kim et al., 2009). 
4.1.4 Colorectal cancer 
PET/CT is recognised in the preoperative evaluation of apparently limited metastatic 
disease, detection of disease recurrence, clarification of equivocal lesions, investigation of 
rising tumour markers, and incidental detection of occult primary colonic tumours 
(Chowdhury et al., 2010). Transrectal ultrasound and MRI provide much better anatomic 
resolution and are of greater value for T staging. The sensitivity for regional N staging is 
low (Kantorva et al., 2003). Yet, in a study of patients with low rectal cancers, FDG-
PET/CT altered treatment plans in 38% of patients largely through the detection of 
unsuspected inguinal adenopathy (Gearhart et al., 2006). PET for diagnosis and staging 
does not generate additional survival effectiveness compared with CT alone but cost 
savings associated with its use and the improvement of therapeutic management (Lejeune 
et al., 2005). 
4.1.5 Hepatic metastases 
Size is a limiting factor and the additional value of PET/CT is not yet fully established 
(Wiering et al., 2008). 
4.1.6 Breast cancer 
The present evidence does not support the routine use of PET or PET-CT for the assessment 
of the clinically negative axilla but is superior to conventional staging for detecting internal 
mammary chain nodes (Cooper et al., 2011, Segaert et al., 2010). FDG-PET/CT changes the 
clinical management in 50% of breast cancer patients with elevated tumour markers and 
negative or equivocal conventional imaging modalities (Filippi et al., 2011). Several studies 
aimed to use PET/CT to monitor therapy response, yet lack sufficient validation (Groheux 
et al., 2011). PET/CT showed clear advantage over CT and PET alone for the diagnosis of 
breast cancer recurrence (Pennant et al., 2010). 
4.1.7 Melanoma 
The combination of PET and CT had a higher sensitivity than either technique alone in 
staging high risk-patients with potentially respectable cancer (Strobel et al., 2007). 
Integrating PET-CT in the management of patients with high risk MM appears to be less 
costly and more accurate by avoiding futile thoracotomies in one of five patients as well as 
by providing a small survival benefit at 10 years (Krug et al., 2010). 
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PET/CT improves baseline staging compared with conventional staging with CT alone 
(Freudenberg et al., 2004) and has been extensively reviewed in this field (Cronin et al., 
2010). PET/CT scanning had a significant predictive value for disease progression and 
survival of DLBCL in post-rituximab treatment; it might be the single most important 
determinant of clinical outcome in patients with the same IPI risk (Yang et al., 2011). 
Nevertheless it is still not proven that the use of interim FDG PET can improve patient 
outcomes (Hutchings et al., 2009).  
4.1.9 Ovarian cancer 
FDG PET/CT is not recommended for primary ovarian cancer detection but is the best 
technique for lesion detection and treatment follow-up (Veena et al., 2010). It alters 
management in close to 60% of patients, detects more sites of disease than abdominal and 
pelvic CT and is superior in the detection of nodal, peritoneal and subcapsular liver disease 
(Fulham et al., 2009). 
4.1.10 Gastrointestinal stromal tumors (GIST) 
PET/CT is the method of choice for staging of GIST because some lesions have only a weak 
FDG uptake. PET/CT was also successfully used for monitoring of imatinib therapy because 
tumour shrinkage is minimal even in histological successful therapy (Antoch et al., 2004).  
4.1.11 Radiotherapy planning  
Nine experts and three IAEA staff evaluated the use of PET in radiotherapy planning and 
considered integrated PET/CT as the best available approach in non-small cell lung cancer, 
head and neck cancers, lymphoma and in esophageal cancers, with promising preliminary 
data in many other cancers (MacManus et al., 2009, Paulino et al., 2003).  
4.1.12 Thyroid cancer 
FDG PET/CT is capable to detect disease in patients with differentiated thyroid carcinoma 
with elevated Tg levels and negative radioiodine scan and the localization of disease in 
patients with medullary thyroid cancer and elevated serum calcitonin levels (Basu et al., 
2011). 124 Iodine PET/CT may serve a role in obtaining lesional dosimetry of I-131 therapy 
(Abraham & Schöder, 2011).   
4.1.13 Prostate cancer 
The role of PET in prostate cancer has not been established yet, but due to the limited 
anatomical information provided by the used tracers, notably radiolabeled choline, PET/CT 
will be mandatory for local therapy planning. 
4.2 Neurology 
We lack evidence that attenuation and scatter correction in the brain is significantly 
improved by CT in contrast to conventional correction. It might however be useful for 
image landmarking in image fusion with MR. 
4.3 Cardiology 
Although the introduction of hybrid PET/CT technology offers the exciting possibility of 
assessing the extent of anatomic CAD (CT coronary angiography) and its functional 
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consequences (ischemic burden) in the same setting, there are technical challenges in the 
implementation of CT-based transmission imaging for attenuation correction (DiCarli et al., 
2007). The clinical potential of PET/CT for the characterization of cardiovascular diseases 
has been reviewed recently (Schwaiger et al., 2010) and is apparently used in clinical routine 
with increasing frequency (Heller et al., 2009). 
5. Current state of clinical SPECT/CT 
Whereas the PET market has entirely focused on hybrid designs, it is still possible to buy 
stand alone SPECT systems, but in view of the commercial success of integrated PET/CT 
scanners, there is an increasing interest in SPECT/CT systems (Buck et al., 2008). World 
wide market sales according to an industry source are in the range of 75% SPECT and 25% 
SPECT/CT with a continuing increase of hybrid devices. 
5.1 Oncology  
The role of hybrid imaging in oncology has been recently reviewed (Chowdhury & 
Scarsbrook, 2008). 
5.1.1 131-I thyroid cancer  
Planar 131-I whole body scan is hampered by many pitfalls (Leitha & Staudenherz, 2003). 
SPECT/CT improves the differentiation between physiologic and pathologic uptake of 
whole body iodine scan (Kohlfürst et al. 2009) and changes the therapeutic approach in a 
significant group of patients (Yamamoto et al., 2003). The unique contribution of a 
diagnostic CT in addition to the information of the 131-I scan is the detection of non-iodine-
avid nodular lung disease, lymph node metastases and lytic bone lesions. It remains to be 
determined to what extent these findings improve patient management. 
5.1.2 Neuroendocrine tumors, neural crest tumors  
Low dose CT improves image interpretation by providing a better anatomic localization of 
SPECT-detected lesions in 41 percent of the patients primarily by improving the 
discrimination between physiological and pathological tracer uptake (Even-Sapir et al., 
2001). Pfannenberg et al., (2003) pointed out that “The problem of false-negative SPECT 
results cannot be solved by SPECT/CT because of inherent low resolution and lack of oral 
and intravenous contrast of the low-dose CT component. SPECT/CT is better than SPECT or 
CT alone but cannot replace high-end CT. Therefore a high end CT component should be 
implemented in the SPECT/CT device to allow for combined acquisition of high-quality 
contrast-enhanced CT in addition to SPECT.” I-123 mIBG SPECT/CT had a sensitivity (93%) 
similar to that (99%) achieved by PET/CT with C-11-HED as a tracer (Franzius et al., 2006). 
A significant impact of SPECT/CT on therapeutic management was also demonstrated by 
Hillel et al., (2006) in neuroendocrine tumors. The addition of clinically relevant information 
for 40% of patients by SPECT/CT compared with SPECT was described by Gabriel et al., 
(2005). Co-registration with CT improves dose calculations in planning radionuclide therapy 
(Tang et al., 2001). 
5.1.3 Lymphoscintigraphy 
SPECT detects nodes missed on planar scintigraphy but stand-alone SPECT lacks 
anatomical landmarks. Pilot studies suggested incremental diagnostic efficacy in many 
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cancers, including melanoma (Even-Sapir et al., 2003), head neck cancer (Wagner et al., 
2007), cervical cancer (Zhang et al., 2006), invasive bladder cancer (Sherif et al., 2006), breast 
cancer (Gallowitsch et al., 2007) and prostate cancer (Vermeeren et al., 2009). 
5.1.4 Prostate cancer 
FDA approved the use of Prostascint (In-111 capromab-pendetide), a monoclonal antibody-
based imaging agent for detecting prostate cancer in 1996 but it was soon realized that the 
low tumour/background ratio and the lack of anatomical information necessitates hybrid 
imaging (Terence et al., 2005). With the limited sensitivity of contrast enhanced CT in 
prostate cancer, the contribution lies mainly in the improvement of topographical 
orientation and mapping for planning of external radiation therapy. 
5.1.5 Dosimetry 
SPECT/CT might be useful for performing valid and clinically applicable dosimetry, for 
improving treatment planning, and for ensuring safe and effective radionuclide therapy 
(Boucek & Turner 2005, Thierens et al., 2005, Prideaux et al., 2007, Lavely et al., 2007). 
5.2 Endocrinology 
5.2.1 99m-Tc MIBI parathyroid adenoma 
CT co-registration is a valuable tool for the precise delineation of parathyroid adenomas 
with little incremental benefit from attenuation correction (Ruf et al., 2007) though others 
have seen little incremental benefit with non-diagnostic CT (Gayed et al., 2005). 
5.3 Cardiology 
SPECT attenuation correction with external sources was introduced in the early 1990s but, 
possibly due to financial and logistic problems got mixed reviews ever since (Dondi et al, 
2004). Ten years later attenuation correction with CT was introduced (Masood et al., 2005) 
and the Society of Nuclear Medicine awarded its 2006 image of the year award to a 
cardiac SPECT/CT study (2006 Image of the year: focus on cardiac SPECT/CT. J Nucl 
Med. 2006; 47:14N–15N). Three different approaches were developed. The first was a low 
dose low resolution CT protocol aimed entirely at attenuation correction of SPECT data 
(Fricke et al., 2005), the second performed additional calcium scoring (Chang et al., 2009) 
and the third combined myocardial perfusion SPECT with a 64-slice CT angiography 
(CTA), initially only available on two different devices with digital fusion of the 
attenuation corrected SPECT and CTA (Gaemperli et al., 2007). Though feasible in 
principle and possibly identifying an independent risk, the value of assessing coronary 
calcifications or coronary morphology as part of a nuclear study needs to be validated in 
large prospective studies and appreciated in the light of the increased radiation exposure. 
At present attenuation correction in myocardial SPECT is especially useful in overweight 
patients and in women, however some degree of misregistration is still seen in the 
majority of the patients (Fricke et al., 2004, Goetze & Wahl, 2007) and CT artefacts may be 
a problem. Recent developments aimed to reduce imaging times by using semiconductor 
detectors and a converging collimator to increase sensitivity and a 3D iterative 
reconstruction utilizing the CT-based attenuation map enabling SPECT acquisitions in 
typically 5 minutes (IQSPECT technology Siemens) (Corbet et al., 2010).  
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5.4 Neurology  
Until now no systematic analysis is available to assess differences between individually 
measured and conventionally calculated attenuation correction. Quantitative receptor 
imaging of fp-cit SPECT could be a perfect candidate for proving this principle. 
5.5 Bone scans  
Presently, SPECT/CT has added value in improved localization and characterization of 
bone lesions, both increasing sensitivity and specificity of bone scintigraphy. This was 
mainly achieved by identifying benign bone conditions with increased bone turnover 
(Utsunomiya et al., 2006). Until the introduction of SPECT/CT this has been routinely 
performed by comparing bone scanning with conventional (planar) X-ray and until now no 
additional benefit over the visual fusion of bone SPECT with planar X-ray, CT, or MRI 
studies has been confirmed (Horger et al., 2007). Thus, the “one-stop-shop” SPECT/CT has 
the drawback of increased radiation exposure. Low dose SPECT/CT may be a feasible 
compromise but may miss osteolytic lesions (Horger et al., 2004). “SPECT-guided CT” may 
be a better solution to the problem if it can be achieved logistically and is supported by the 
hybrid system (Roemer et al., 2006).  Playing the devils advocate one may also assume that 
some of the lesions described as indeterminate in those scans could have been correctly 
identified by classical image features like pattern recognition (Puig et al., 1998) as it has been 
the clinical practice in times before hybrid imaging has hit the market. 
5.6 Infections  
Ga-67 scintigraphy, In-111 and Tc-99m labelled white blood cell scintigraphy is used to 
visualize infection. Physiological uptake and excretion and the lack of topographical 
information may hamper scan interpretation. SPECT/CT has been useful in the 
differentiation between bone and soft tissue infection (Fillippi et al., 2009). 
6. Unsolved challenges 
6.1 Real integration in stead of two devices “glued” together 
Some of the early systems required two consoles to operate the system, one for the CT and 
one for the PET or SPECT. Some early PET/CTs incorporated a patient bore size that started 
at 70 cm for the CT and narrowed to about 59 cm for the PET system. In contrast to the 
statements of all manufacturers most commercially available systems are in essence still two 
separate machines (Figure 3).  
The software of commercially available systems although combined under an apparently 
homogeneous surface still shows it different origins. Until the development of new detector 
types for both signals, movement in the interval between SPECT and CT data collection will 
continue to pose a problem.  
6.2 Imaging protocols 
A simple combination of traditional imaging protocols might not be the optimal use of 
hybrid imaging. Procedure guidelines and protocols are available for PET/CT (Boellaard et 
al., 2010) and SPECT/CT (Delbeke et al., 2006, Buck et al., 2008) but little efforts have been 
published so far to downsize conventional CT protocols if combined with Nuclear Medicine. 
The possible trade off of this has not been investigated, yet. Discussions have already begun 
about the reimbursement of diagnostic imaging as it is not apparent to most that a previous  
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Fig. 3. Siemens Symbia T6: Left: Gantry of the dual head gamma camera, Center: both parts 
separated during service, Right: Gantry of the 6 slice MD CT 
PET/CT study might not run other CT investigations obsolete.  On the other hand, due to 
the higher number of CT investigations performed, many patients will already have 
undergone a diagnostic CT investigation before referral to their first Nuclear Medicine study 
and the duplicated CT further boosts the radiation burden. Current trends indicate that 
more and more centres use contrast enhancement and some regard the CT contrast agents 
and PET tracers as complementary (Antoch et al., 2004) but this may reflect common 
practice in radiology more than hard scientific evidence. 
6.3 Education and training, data reporting 
At present Nuclear Medicine and Radiology are different specialities in many countries with 
different training and licensing systems. Consequently the results of PET/CT and 
SPECT/CT require the competency and accreditation of individuals from both Nuclear 
Medicine and Radiology. Proposals for future training models have been put forward 
(White Paper, 2007) but first studies claim that only minimal additional training may be 
necessary to interpret both modalities (Narayanan et al., 2011). None of the commercially 
available RIS-NIS programmes is capable of simultaneous data reporting and validation by 
two different professionals. Standardization is mandatory as a recent survey (Cuocolo & 
Breatnach, 2010) revealed a wide heterogeneity in the current practice of multimodality 
imaging in Europe.  
6.4 Diagnostic pathways 
All current clinical recommendations are based on the sequential use of different imaging 
modalities. If hybrid imaging should be used to its full diagnostic utility, we will have to re-
write conventional diagnostic paths as in many cases the optimized approach will start with 
hybrid imaging. However most of these pathways assume that the referrer has considerably 
narrowed the spectrum of possible differential diagnoses for a given problem, otherwise 
many conventional imaging steps will be necessary to narrow the problem to such an extent 
that a tailored approach is possible. 
6.5 Forensic liabilities 
The new hybrid devices produce a lot of additional information, not necessarily expected by 
the referrer. Data are accumulating that unexpected findings in PET/CT and SPECT/CT 
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(Goetze & Wahl 2007) as solitary pulmonary nodules, pneumonitis, and pleural effusion 
have clinical significance. The same problem has occurred in coronary CT protocols (Onuma 
et al., 2006, Schietinger et al., 2008). 
6.6 Improved PET/CT correction, quantitative imaging 
Whereas PET imaging was at least semi quantitative right from the start, quantitative 
SPECT has – in spite of early efforts (Rosenthal et al., 1995) – never reached prime time. The 
contribution of scatter, collimator response, depth dependent resolution and partial volume 
effect for accurate quantification have been determined for some investigations (Buvat et al., 
2000), but only few data are available for the additional utility of CT for advanced data 
processing (Shcherbinin et al., 2008). On the other hand, contrast media and CT artefacts 
may severely hamper quantification of PET or SPECT (Sureshbabu & Mawlawi, 2005).  
6.7 Costs 
It is often overlooked that the increased costs for hybrid imaging are not only due to 
equipment costs but also to room preparation and energy supply. In those institutions 
where only Nuclear Medicine or Radiology has been practiced in the past, structural 
radiation protection for the other modality has to be installed. CT has a higher energy 
demand than conventional gamma cameras and produces more heat, thus energy supply 
and air conditioning have to be adapted. Usually hybrid systems require larger space than 
conventional systems. Both, radiation protection and space requirements stress the statics of  
some buildings.  
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